Compare Lufax Holding Ltd (LU) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs McKesson Corporation — how do they compare? Lufax Holding Ltd trades at $1.4 (market cap $2.41B), while McKesson Corporation trades at $827.7 (market cap $97.35B). The key difference: McKesson Corporation is far larger — about 40.4× Lufax Holding Ltd's market cap, and McKesson Corporation pays a 0.39% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| LU | MCK | |
|---|---|---|
Market Cap | $2.41B | $97.35B |
Sector | Technology | Health |
52-Week High | $4.40 | $995.69 |
52-Week Low | $1.23 | $659.01 |
Enterprise Value | — | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $1.36, down 2.16% today. The stock shows a mixed technical picture with a neutral overall signal and bearish moving averages. Fundamentally, the company reported a net loss of $2.1B on $23.1B revenue for 2025, with negative profit margins and returns. Analyst consensus is bullish with 61.5% buy ratings, but sentiment is clouded by multiple class-action lawsuits announced in May 2026 alleging securities fraud.
The outlook is cautious. While low valuation ratios (P/S 0.35, P/B 0.1) and analyst support suggest potential upside, persistent losses and significant legal overhangs pose substantial risks. Investor focus remains on the company's ability to return to profitability amid these challenges.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
